Wayrilz
Payments companies reported to CMS as associated with Wayrilz. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Wayrilz, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Wayrilz
These are the largest totals companies reported as associated with Wayrilz. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Asad Dean | Fort Worth, TX | Hematology & Oncology | $69,047.94 |
| Michael Tarantino | Peoria, IL | Pediatric Hematology-Oncology | $68,699.44 |
| Amit Mehta | Cary, NC | Hematology & Oncology | $49,646.70 |
| Trevor Feinstein | Fayetteville, GA | Hematology & Oncology | $42,758.11 |
| Jamie Koprivnikar | Hackensack, NJ | Medical Oncology | $24,415.01 |
| Edward Pearson | Dallas, TX | Hematology & Oncology | $19,308.40 |
| George Yaghmour | Los Angeles, CA | Hematology & Oncology | $15,914.89 |
| Khuda Khan | Louisville, KY | Hematology & Oncology | $14,447.34 |
| Akshat Jain | Redlands, CA | Pediatric Hematology-Oncology | $13,297.00 |
| Aaron Zarnosky | Grand Rapids, MI | Physician Assistant | $12,522.47 |
Prescribed Wayrilz?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.